loading

Finanzdaten der Viking Therapeutics Inc-Aktie (VKTX)

Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
Enddatum des Zeitraums 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30
Periodenlänge 3 Monate 3 Monate 3 Monate 3 Monate 3 Monate
Revenues
-
- - - -
Operating Expenses
34.44%
74.57
55.47 46.24 36.56 34.05
Operating Income/Loss
34.44%
-74.57
-55.47 -46.24 -36.56 -34.05
Income/Loss From Continuing Operations Before Tax
43.68%
-65.56
-45.63 -35.42 -24.94 -22.25
Income/Loss From Continuing Operations After Tax
43.68%
-65.56
-45.63 -35.42 -24.94 -22.25
Net Income/Loss
43.68%
-65.56
-45.63 -35.42 -24.94 -22.25
Preferred Stock Dividends And Other Adjustments
-
- - - -
Attributable To Noncontrolling Interest
-
- - - -
Basic Average Shares
0.06%
112.13
112.07 0.775 110.91 110.39
Diluted Average Shares
0.06%
112.13
112.07 0.775 110.91 110.39
Basic Earnings Per Share
41.46%
-0.58
-0.41 -0.32 -0.22 -0.20
Diluted Earnings Per Share
41.46%
-0.58
-0.41 -0.32 -0.22 -0.20
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic
-
- - - -
$86.64
price up icon 1.40%
$27.54
price up icon 0.58%
$25.98
price up icon 9.16%
$112.46
price up icon 8.66%
$145.10
price up icon 1.80%
biotechnology ONC
$341.80
price up icon 7.24%
Kapitalisierung:     |  Volumen (24h):